MNEXSPIKE | FDA MNEXSPIKE is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) MNEXSPIKE is
mNEXSPIKE® (COVID-19 Vaccine, mRNA) 2025-2026 Formula mNEXSPIKE® (COVID-19 Vaccine, mRNA) 2025-2026 FormulaAustralia Japan Hong Kong South Korea Taiwan Singapore France Germany Italy Netherlands Spain Switzerland United Kingdom Poland Canada United States LATAM LATAM
Introducing mNEXSPIKE: Moderna’s New COVID-19 Vaccine I am proud to share that mNEXSPIKE®, our new COVID-19 vaccine, is now approved in the U S , marking Moderna’s third approved product and fifth vaccine program to achieve positive Phase 3 results This timely approval will allow for the use of mNEXSPIKE in all adults 65 and older, as well as individuals aged 12-64 with one or more underlying conditions that puts them at high risk for severe
News Release - Moderna Moderna's combination vaccine candidate against influenza and COVID-19, mRNA-1083, includes mRNA-1283 That vaccine candidate recently announced positive results in its separate Phase 3 trial Moderna plans to present the Phase 3 clinical data for mRNA-1283 at an upcoming conference as well as submit it for publication
FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE Moderna has announced the FDA approval of a new, lower-dose messenger RNA (mRNA) vaccine against COVID-19, called mNEXSPIKE (mRNA-1283) (1) The product joins Moderna’s original COVID vaccine, Spikevax (mRNA-1273), and mRESVIA, a vaccine for respiratory syncytial virus, among the company’s properties that have been approved by FDA (1,2)